Top

Published in:

01-04-2020 | Chronic Kidney Disease | Capsule Commentary

Capsule Commentary on Kurani et al., Use of Potentially Nephrotoxic Medications by U.S. Adults with Chronic Kidney Disease: NHANES, 2011–2016

Author: Julie Machen, MD

Published in: Journal of General Internal Medicine | Issue 4/2020

Excerpt

This study by Kurani et al.¹ examined the prevalence of the use of potentially inappropriate medications (PIM) in patients with chronic kidney disease (CKD), using a cross-sectional analysis of 2011–2016 NHANES data. The authors also explored the relationship between CKD stage, patient awareness of CKD, and PIM use. Results showed that PIM use is common in patients with CKD, with > 50% of patients across all CKD stages using PIM. Patient unawareness of their kidney disease was high, especially in patients with stage 3 CKD (91.6% in stage 3a, 73.1% in stage 3b). There was no association between patient awareness of CKD and odds of PIM use. …

Kurani SS, Jeffery MM, Thorsteinsdottir B, Hickson LJ, Barreto EF, Haag JD, Giblon R, Shah ND, McCoy RG. Use of Potentially Nephrotoxic Medications by U.S. Adults with Chronic Kidney Disease: NHANES, 2011-2016. J Gen Intern Med. DOI: https://doi.org/10.1007/s11606-019-05557-8

KDIGO. KDIGO 2012 Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013;3(1):1–150.CrossRef

Stevens LA, Li S, Wang C, Huang C, Becker BN, Bomback AS, et al. Prevalence of CKD and comorbid illness in elderly patients in the United States: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis 2010;55(3 Suppl 2):S23–33.CrossRef

Tseng CL, Soroka O, Maney M, Aron DC, Pogach LM. Assessing potential glycemic overtreatment in persons at hypoglycemic risk. JAMA Intern Med 2014;174(2):259–68.CrossRef

Zhan M, St. Peter WL, Doerfler RM, Woods CM, Blumenthal JB, Diamantidis CJ, et al. Patterns of NSAIDs use and their association with other analgesic use in CKD. Clin J Am Soc Nephrol 2017;12(11):1778–86.CrossRef

Title: Capsule Commentary on Kurani et al., Use of Potentially Nephrotoxic Medications by U.S. Adults with Chronic Kidney Disease: NHANES, 2011–2016
Author: Julie Machen, MD
Publication date: 01-04-2020
Publisher: Springer International Publishing
Keyword: Chronic Kidney Disease
Published in: Journal of General Internal Medicine / Issue 4/2020
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI: https://doi.org/10.1007/s11606-020-05714-4

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Capsule Commentary on Kurani et al., Use of Potentially Nephrotoxic Medications by U.S. Adults with Chronic Kidney Disease: NHANES, 2011–2016

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 4/2020

Why Do Physicians Pursue Cascades of Care After Incidental Findings? A National Survey

Too Many Don’ts and Not Enough Do’s? A Survey of Hospitals About Their Portal Instructions for Patients

SAPHO Syndrome from Hidradenitis Suppurativa

Capsule Commentary on Weber et al.’s Development and Establishment of Initial Validity Evidence for a Novel Tool for Assessing Trainee Admission Notes

The Partnership to Improve Diabetes Education Trial: a Cluster Randomized Trial Addressing Health Communication in Diabetes Care

Challenges and Opportunities for Patients Released from Correctional Facilities: a Qualitative Analysis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page